NO20074318L - Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer - Google Patents

Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer

Info

Publication number
NO20074318L
NO20074318L NO20074318A NO20074318A NO20074318L NO 20074318 L NO20074318 L NO 20074318L NO 20074318 A NO20074318 A NO 20074318A NO 20074318 A NO20074318 A NO 20074318A NO 20074318 L NO20074318 L NO 20074318L
Authority
NO
Norway
Prior art keywords
amyloidosis
manufacture
treatment
fatty acid
acid composition
Prior art date
Application number
NO20074318A
Other languages
English (en)
Other versions
NO343234B1 (no
Inventor
Morten Bryhn
Knut Sletten
Gunilla Torstensdot Westermark
Olof Per Westermark
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of NO20074318L publication Critical patent/NO20074318L/no
Publication of NO343234B1 publication Critical patent/NO343234B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Denne oppfinnelsen vedrører anvendelsen av en fettsyresammensetning som innbefatter minst (all-Z omega-3)-4,7,10,13,16,19-dokosaheksaensyre (DHA) for fremstilling av et medisinsk produkt eller et næringsmiddel for behandling og/eller forebygging av amyloidoserelaterte sykdommer. Den foreliggende oppfinnelsen vedører også en fremgangsmåte for behandling og/eller forebygging av amyloidose realterte sykdommer, slik som IgA nefropati.
NO20074318A 2005-01-24 2007-08-23 Fettsyresammensetning som inneholder DHA og EPA for behandling og/eller forebygging av amyloidose relaterte sykdommer NO343234B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64560405P 2005-01-24 2005-01-24
SE0500174 2005-01-24
PCT/IB2006/000106 WO2006077495A1 (en) 2005-01-24 2006-01-24 Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases

Publications (2)

Publication Number Publication Date
NO20074318L true NO20074318L (no) 2007-10-24
NO343234B1 NO343234B1 (no) 2018-12-17

Family

ID=36692011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074318A NO343234B1 (no) 2005-01-24 2007-08-23 Fettsyresammensetning som inneholder DHA og EPA for behandling og/eller forebygging av amyloidose relaterte sykdommer

Country Status (7)

Country Link
US (2) US20090054523A1 (no)
EP (1) EP1845999A4 (no)
JP (1) JP5503846B2 (no)
KR (1) KR101253696B1 (no)
CA (1) CA2594781A1 (no)
NO (1) NO343234B1 (no)
WO (1) WO2006077495A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
KR100879816B1 (ko) 2007-05-31 2009-01-22 학교법인 일송학원 꽁치류의 가수분해물을 포함하는 허혈성 뇌혈관질환 예방또는 개선용 조성물
PT2374452T (pt) 2008-12-05 2019-10-31 Ajinomoto Kk Composição de nutrientes
CN104042600A (zh) * 2009-02-02 2014-09-17 帝斯曼知识产权资产有限公司 改善认知功能和降低心率的方法
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
US20100239660A1 (en) * 2009-03-19 2010-09-23 Doughman Scott D Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
US8124574B2 (en) 2009-10-12 2012-02-28 Conopco, Inc. Mild, foaming liquid cleansers comprising low levels of fatty isethionate product and low total fatty acid and/or fatty acid soap content
US8105994B2 (en) 2010-03-31 2012-01-31 Conopco, Inc. Personal wash cleanser comprising defined alkanoyl compounds, defined fatty acyl isethionate surfactant product and skin or hair benefit agent delivered in flocs upon dilution
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
KR20220010415A (ko) * 2020-07-17 2022-01-25 대봉엘에스 주식회사 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
JPH07268385A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 魚臭が低減されたカツオおよび／またはマグロ油
JPH09511533A (ja) * 1994-09-19 1997-11-18 ザ、プロクター、エンド、ギャンブル、カンパニー 顆粒状漂白組成物
JPH08143454A (ja) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6395778B1 (en) * 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
CN1380058A (zh) * 2001-04-10 2002-11-20 上海体育运动技术学院 用于促进人体自身epa、dha合成的药物
US20030077342A1 (en) * 2001-10-09 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing eicosapentaenoic acid
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction

Also Published As

Publication number Publication date
JP5503846B2 (ja) 2014-05-28
EP1845999A4 (en) 2010-09-22
CA2594781A1 (en) 2006-07-27
NO343234B1 (no) 2018-12-17
KR20070104917A (ko) 2007-10-29
US20090054523A1 (en) 2009-02-26
EP1845999A1 (en) 2007-10-24
US20120277317A1 (en) 2012-11-01
WO2006077495A1 (en) 2006-07-27
KR101253696B1 (ko) 2013-04-12
JP2008528475A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
ATE462428T1 (de) Behandlung von entzündlichen erkrankungen
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
CY1109420T1 (el) Ενωσεις εστερα ν-αλκυλκαρβονυλ-αμινοξεος και ν-αλκυλκαρβονυλ-αμινο λακτονης και χρηση αυτων
MX336723B (es) Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
MY147503A (en) Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MX2024011254A (es) Moduladores de nlrp3
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MY201921A (en) Agent for preventing or treating fat-associated diseases and/or inflammation
MX2022000712A (es) Moduladores de nlrp3.
NO20092473L (no) Kombinasjon
PH12022552447A1 (en) Nlrp3 modulators
EA201991933A1 (ru) Лечение гингивита
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
WO2004017949A3 (de) Prophylaxe und therapie von infektionserkrankungen mit amitryptilin oder imipramin oder desipramin oder fgf oder einem anticeramid antikörper oder cyclodextrin oder nystatin oder filipin
TW200612903A (en) Use of trisubstituted benzopyranones
PH12016501111A1 (en) Composition comprising ferric saccharate and high concentrations of microencapsulated lc-pufa with a reduced off taste
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees